People: Mesoblast Ltd (MSB.AX)
26 Jun 2017
Dr. Ben-Zion Weiner, Ph.D., is an Non-Executive Independent Director of Mesoblast Ltd. In a 37-year career at Teva Pharmaceutical Industries Ltd, he held various senior research and development positions, including Senior Vice President of Global Research and Development. Dr Weiner twice received the Rothschild Prize for industrial innovation – for the development of Copaxone for the treatment of multiple sclerosis, and alpha D3 for kidney and bone disorders. He is on the Board of Directors at Novaremed Ltd., the scientific advisory board at E-QURE Corp. and Breed IT, Corp. and has served on the Board of Directors at Geffen Biomed Investments Ltd (2010-2013), XTL Biopharmaceuticals Limited (2012-2013) and Breed IT, Corp.
|Total Annual Compensation, AUD||138,250|
|Restricted Stock Awards, AUD||--|
|Long-Term Incentive Plans, AUD||--|
|All Other, AUD||42,737|
|Fiscal Year Total, AUD||180,987|